A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

Clinical trial NCT07469488 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07469488
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

NSCLC (Advanced Non-small Cell Lung Cancer)VTE (Venous Thromboembolism)Rash Due to Epidermal Growth Factor Receptor Inhibitors Infusion Reaction

Start date: 2026-04-30
Primary completion: 2029-08-31
Enrollment: 122

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.